泰邦生物集团 China Biologic Products 中国生物制品  
China Biologic Products, Inc. (NASDAQ: CBPO) 是国家承认的最大的非国有血浆生物医药制品公司，通过我们旗下的山东泰邦生物制品有限公司、贵阳大林生物科技公司，以及我们投资于西安回天血液制品的产品，我们已经成为了血浆生物医药制品行业的综合供应商，我们有能力跨越，以从血浆存储，到研究发展，到产品制造和全面商业化。我们的主要产品，人类血蛋白和免疫球蛋白，最常被用于治疗威胁生命的各种情况，如低白蛋白，血友病及其他血液病。我们目前有20个销售血浆产品和新产品的生产线，以推动大中国市场未来的血液产品市场的发展。为了配合我们的有机增长，我们继续寻求战略收购机会，扩大我们在中国地区的血浆储备能力，并加强我们的研发和技术上的能力。

China Biologic Products Inc。泰邦生物是一家在纳斯达克交易所上市的公司，股票代码CBPO，公司总部设于中国北京市。泰邦生物是最大的的非国有制的血浆生物医药制品公司，旗下拥有子公司山东泰邦生物制品有限公司，贵阳大林生物科技公司，以及西安回天血液制品公司的股份，我们已经成为了在血浆收集、开发和生产新的血液药物、并将其终端产品商品化的综合供应商。我们的产品主要针对紧急医疗情况，以及预防和治疗威胁生命的疾病。我们的产品在的终端用户是医院和其他卫生保健机构。

China Biologic Products, Inc. (Nasdaq: CBPO), is one of the China’s largest non-state-owned fully integrated plasma-based biopharmaceutical companies. Our products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases that include rabies, tetanus, and hepatitis B.

Our core capabilities include plasma collection, research and development, production, and commercialization of biopharmaceutical products.

Currently we produce more than 20 plasma-based products and have a pipeline of new and developing products to drive our future in China’s growing plasma market. To complement our organic growth, we consider acquisitions to expand our plasma collection capabilities in China. We are constantly at work to enhance our R&D and technological capabilities to create new products and to improve our existing products and processes.

We sell directly to hospitals and other healthcare facilities in China and are reducing the use of independent distributors.

Our headquarters is in the city of Beijing. We manufacture in our indirect majority-owned subsidiaries, Shandong Taibang Biological Products and Guiyang Dalin Biologic Technologies, and have an equity investment in Xi’an Huitian Blood Products.